[go: up one dir, main page]

IL160065A0 - 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases - Google Patents

17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Info

Publication number
IL160065A0
IL160065A0 IL16006502A IL16006502A IL160065A0 IL 160065 A0 IL160065 A0 IL 160065A0 IL 16006502 A IL16006502 A IL 16006502A IL 16006502 A IL16006502 A IL 16006502A IL 160065 A0 IL160065 A0 IL 160065A0
Authority
IL
Israel
Prior art keywords
17beta
inhibitors
treatment
hydroxysteroid dehydrogenase
dependent diseases
Prior art date
Application number
IL16006502A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL160065A0 publication Critical patent/IL160065A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16006502A 2001-09-06 2002-09-05 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases IL160065A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31771501P 2001-09-06 2001-09-06
PCT/US2002/028181 WO2003022835A1 (en) 2001-09-06 2002-09-05 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Publications (1)

Publication Number Publication Date
IL160065A0 true IL160065A0 (en) 2004-06-20

Family

ID=23234950

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16006502A IL160065A0 (en) 2001-09-06 2002-09-05 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL160065A IL160065A (en) 2001-09-06 2004-01-26 Derivatives of piperazine and piperidine as inhibitors of 17 beta-hydroxysteroid type 3 dehydrogenase and pharmaceutical preparations containing them for the treatment of androgen-dependent diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160065A IL160065A (en) 2001-09-06 2004-01-26 Derivatives of piperazine and piperidine as inhibitors of 17 beta-hydroxysteroid type 3 dehydrogenase and pharmaceutical preparations containing them for the treatment of androgen-dependent diseases

Country Status (29)

Country Link
US (3) US6903102B2 (es)
EP (1) EP1423381B1 (es)
JP (1) JP4320252B2 (es)
KR (1) KR100991616B1 (es)
CN (1) CN1551878B (es)
AR (1) AR036492A1 (es)
AT (1) ATE350375T1 (es)
AU (1) AU2002326823B2 (es)
BR (1) BR0212378A (es)
CA (1) CA2459311C (es)
CY (1) CY1106521T1 (es)
DE (1) DE60217363T2 (es)
DK (1) DK1423381T3 (es)
EC (1) ECSP045004A (es)
ES (1) ES2276950T3 (es)
HU (1) HUP0402629A3 (es)
IL (2) IL160065A0 (es)
MX (1) MXPA04002167A (es)
MY (1) MY141661A (es)
NO (1) NO327254B1 (es)
NZ (1) NZ530810A (es)
PE (1) PE20030703A1 (es)
PL (1) PL369108A1 (es)
PT (1) PT1423381E (es)
RU (1) RU2315763C2 (es)
SI (1) SI1423381T1 (es)
TW (1) TWI329108B (es)
WO (1) WO2003022835A1 (es)
ZA (1) ZA200401456B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
PE20030705A1 (es) * 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
JP4614770B2 (ja) 2002-11-18 2011-01-19 シェーリング コーポレイション アンドロゲン依存性疾患を処置するための１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ３インヒビター
US7053091B2 (en) * 2002-12-17 2006-05-30 Schering Corporation 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
AR046901A1 (es) * 2003-12-17 2005-12-28 Schering Corp Composiciones farmaceuticas
JP4866740B2 (ja) 2004-01-07 2012-02-01 アンドルシェルシュ・インコーポレイテッド へリックス１２指向ステロイド系医薬品
US7138246B2 (en) 2004-03-01 2006-11-21 Bristol-Myers Squibb Company Methods for identifying or screening for agents that modulate 17β-HSD3
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US8884061B2 (en) * 2006-03-03 2014-11-11 Colorado State University Research Foundation Compositions and methods of use of electron transport system inhibitors
MX2008013644A (es) * 2006-04-24 2009-03-06 Lilly Co Eli Pirrolidinonas sustituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
ES2378574T3 (es) * 2006-04-24 2012-04-16 Eli Lilly & Company Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
JP5179486B2 (ja) 2006-06-28 2013-04-10 アムジエン・インコーポレーテツド グリシン輸送体−１阻害剤
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8273883B2 (en) 2007-02-09 2012-09-25 Kaneka Corporation Method for producing optically active 2-arylpiperazine derivative
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
EP2744808A4 (en) 2011-08-16 2015-04-01 Sinai School Medicine Tricyclic compounds as anticancer agents
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
EP3013845B1 (en) 2013-06-25 2020-03-18 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17b-hydroxysteroid dehydrogenase, type 1
US9850272B2 (en) 2013-06-25 2017-12-26 Forendo Pharma Ltd. Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
CN105518015B (zh) 2013-06-25 2017-09-15 佛恩多制药有限公司 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
WO2015036892A1 (en) * 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
CN103755626A (zh) * 2014-01-23 2014-04-30 安徽安腾药业有限责任公司 一种贝托斯汀关键中间体的合成方法
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2016102776A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd Prodrugs of 17.beta.-hsd1 -inhibitors
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
ES3014630T3 (en) 2016-07-29 2025-04-23 Janssen Pharmaceutica Nv Niraparib for use in a method of treating prostate cancer
BR112019022137A2 (pt) 2017-05-04 2020-05-12 Basf Se Usos de compostos, compostos da fórmula i, composição agroquímica e método para combater fungos nocivos fitopatogênicos
NZ760155A (en) 2017-06-08 2022-09-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5
KR20210114390A (ko) 2018-12-05 2021-09-23 포렌도 파마 리미티드 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물
WO2021003295A1 (en) * 2019-07-02 2021-01-07 Regeneron Pharmaceuticals, Inc. Modulators of hsd17b13 and methods of use thereof
CN114341100A (zh) 2019-08-28 2022-04-12 联合利华知识产权控股有限公司 用于亮肤的新型化合物
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195015B1 (en) 1984-08-02 1992-05-13 LABRIE, Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
AU5281990A (en) 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
DK0943328T3 (da) 1989-07-07 2004-10-18 Endorech Inc Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
EP0595796B1 (en) 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FI931600A7 (fi) 1990-10-10 1993-05-17 Schering Corp Diaryylimetyylipiperidiinien tai piperatsiinien pyridiinit ja pyridiin i-N-oksidijohdokset, ja yhdisteet ja menetelmät niiden käyttämiseksi
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
DK0635012T3 (da) 1992-03-27 1996-08-19 Schering Corp Bis-aryl-carbinolderivater uden broer, præparater indeholdende disse og fremgangsmåder til anvendelse af disse
DE69327541T2 (de) 1992-10-28 2000-08-10 Merck Sharp & Dohme Ltd., Hoddesdon 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
CA2150951A1 (en) 1992-12-14 1994-06-23 Angus Murray Macleod 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
DE69329649D1 (de) 1993-05-17 2000-12-14 Endorech Inc Verbesserte antiandrogene
JPH08511522A (ja) 1993-06-07 1996-12-03 メルク エンド カンパニー インコーポレーテッド ニューロキニンアンタゴニストとしてのスピロ置換アザ環
AU685212B2 (en) 1994-01-13 1998-01-15 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
US6063926A (en) 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
US6204265B1 (en) 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
WO2000043008A1 (en) 1999-01-25 2000-07-27 Smithkline Beecham Corporation Anti-androgens and methods for treating disease
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
IL150849A0 (en) 2000-02-11 2003-02-12 Vertex Pharma Piperzine and piperidine derivatives and pharmaceutical compositions containg the same

Also Published As

Publication number Publication date
IL160065A (en) 2009-07-20
CY1106521T1 (el) 2012-01-25
CN1551878B (zh) 2011-08-10
HK1062677A1 (en) 2004-11-19
MXPA04002167A (es) 2004-06-29
US20060069103A1 (en) 2006-03-30
AR036492A1 (es) 2004-09-15
ES2276950T3 (es) 2007-07-01
MY141661A (en) 2010-05-31
WO2003022835A1 (en) 2003-03-20
KR20040031042A (ko) 2004-04-09
JP2005502705A (ja) 2005-01-27
CA2459311C (en) 2010-08-03
ZA200401456B (en) 2004-10-19
HUP0402629A3 (en) 2009-09-28
KR100991616B1 (ko) 2010-11-04
CA2459311A1 (en) 2003-03-20
US7138396B2 (en) 2006-11-21
EP1423381A1 (en) 2004-06-02
EP1423381B1 (en) 2007-01-03
US20060014755A1 (en) 2006-01-19
RU2004110410A (ru) 2005-10-20
DE60217363T2 (de) 2007-10-11
DE60217363D1 (de) 2007-02-15
PL369108A1 (en) 2005-04-18
ECSP045004A (es) 2004-04-28
HUP0402629A2 (hu) 2005-05-30
TWI329108B (en) 2010-08-21
SI1423381T1 (sl) 2007-04-30
CN1551878A (zh) 2004-12-01
US7432268B2 (en) 2008-10-07
NO327254B1 (no) 2009-05-25
NO20041452L (no) 2004-06-04
US20040132736A1 (en) 2004-07-08
NZ530810A (en) 2006-05-26
US6903102B2 (en) 2005-06-07
PE20030703A1 (es) 2003-08-21
JP4320252B2 (ja) 2009-08-26
RU2315763C2 (ru) 2008-01-27
BR0212378A (pt) 2004-10-19
ATE350375T1 (de) 2007-01-15
AU2002326823B2 (en) 2005-12-15
PT1423381E (pt) 2007-04-30
DK1423381T3 (da) 2007-05-07

Similar Documents

Publication Publication Date Title
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL209842A0 (en) Compounds for the treatment of metabolic disorders
PL374846A1 (en) New compounds for the inhibition of rotamases and use thereof
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003290799A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
SI1200114T1 (sl) Inhibitorji ppar delta za zdravljenje kardiovaskularnih bolezni
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2003291368A8 (en) Compounds for the treatment of tobacco dependence and withdrawal
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2003265281A8 (en) Methods and compositions for the enhancement of wound healing
EP1458403A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND CLINICAL REMISSION OF PSORIASIS
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2003273192A8 (en) Compounds and compositions for the treatment of diabetes and diabetes-related disorders